Sign In
Buy CTSO
$0.361
+0.0108 (+3.08%)
At Close: Jul 31, 2026
CytoSorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented at EuroPCR 2025
09:27am, Thursday, 22'nd May 2025
Real-World Analysis Shows Statistically Significant Reduction in Severe Bleeding and Transfusion Needs in CABG Patients on the Blood Thinner, Ticagrelor, with CytoSorbents Therapy PRINCETON, N.J. , Ma
Cytosorbents Corporation (CTSO) Q1 2025 Earnings Call Transcript
09:37pm, Wednesday, 14'th May 2025
Cytosorbents Corporation (NASDAQ:CTSO ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Adanna Alexander - Investor Relations Phillip Chan - Chief Executive Officer Makis
CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update
04:01pm, Wednesday, 14'th May 2025
PRINCETON, N.J. , May 14, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using
CytoSorbents Provides Regulatory Update for DrugSorb-ATR
04:15pm, Thursday, 01'st May 2025
PRINCETON, N.J., May 1, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac
CytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights
07:00am, Tuesday, 29'th Apr 2025
PRINCETON, N.J. , April 29, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using
CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program
07:00am, Monday, 21'st Apr 2025
PRINCETON, N.J. , April 21, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using
CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller
07:00am, Thursday, 17'th Apr 2025
Ms. Grossman brings 25 years of accomplished finance and accounting experience in global, publicly-traded companies Company announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PRINCETON,
CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America
07:00am, Monday, 14'th Apr 2025
PRINCETON, N.J. , April 14, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using
CytoSorbents Extends Expiration Date of Outstanding Series B Right Warrants
07:00am, Friday, 04'th Apr 2025
PRINCETON, N.J. , April 4, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using b
Cytosorbents Corporation (CTSO) Q4 2024 Earnings Call Transcript
07:51pm, Monday, 31'st Mar 2025
Cytosorbents Corporation (NASDAQ:CTSO ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Adanna Alexander – IR Phillip Chan - CEO & Director Peter Mariani - CFO Confer
CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
04:15pm, Monday, 31'st Mar 2025
2024 marked by strong commercial execution and improved operating leverage Company continues to expect DrugSorb-ATR regulatory decisions from Health Canada and US FDA in 2025 Successful Rights Offerin
CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit
07:00am, Friday, 21'st Mar 2025
The Company reaffirms previously provided preliminary financial results for the quarter and full year ended December 31, 2024, and continues to expect regulatory decisions on DrugSorb™-ATR marketing
CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller
07:00am, Tuesday, 04'th Mar 2025
PRINCETON, N.J., March 04, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery usi
CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue
07:00am, Friday, 03'rd Jan 2025
Fourth quarter product revenue growth estimated at 22% to 25% year-over-year Fourth quarter gross margin estimated to improve to approximately 70% Management will host in-person investor meetings in S
CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week
07:00am, Thursday, 12'th Dec 2024
PRINCETON, N.J., Dec. 12, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery usin
